The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer

References

• Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol.14, 2738–2746 (1996).
   PubMed Web of Science ®Google Scholar
• Lamerato L, Havstad S, Gandhi S, Jones D, Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. J. Clin. Oncol.23(16S), 62s (2005) (Abstract 738).
   Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365, 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl Cancer Inst.93, 684–690 (2001).
   PubMed Web of Science ®Google Scholar
• Baum M, Budzar AU, Cuzick J et al; for the ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet359, 2131–2139 (2002). Erratum in: Lancet360, 1520 (2002).
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med.350, 1081–1092 (2004). Erratum in: N. Engl. J. Med.351, 2461 (2004).
   PubMed Web of Science ®Google Scholar
• Thürlimann B, Keshaviah A, Coates AS et al. for the Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med.353, 2747–2757 (2005).
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol.21, 2101–2109 (2003).
   PubMed Web of Science ®Google Scholar
• Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol.23, 619–629 (2005).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Gelber RD, Coates AS. What are the long-term effects of chemotherapy and hormonal therapy for early breast cancer? Nat. Clin. Pract. Oncol.2, 440–441 (2005).
   PubMedGoogle Scholar
• Letrozole (Femara) summary of product characteristics. Novartis Pharmaceuticals AG, Basel, Switzerland (2006).
   Google Scholar
• Letrozole (Femara) package insert. Novartis Pharmaceuticals Corp., East Hanover, NJ, USA (2005).
   Google Scholar
• Geisler J, Ekse D, Helle H, Eystein Lønning P. Letrozole suppresses tissue and plasma estradiol, estrone and estrone sulfate more effectively compared to anastrozole. Breast Cancer Res. Treat.100(Suppl. 1), S23 (2006) (Abstract 103).
   PubMedGoogle Scholar
• Dixon JM, Renshaw L, Young O et al. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. J. Clin. Oncol.24(18S), 15s (2006) (Abstract 552).
   Web of Science ®Google Scholar
• Dixon JM, Renshaw L, Young O et al. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer Ann. Oncol.17(Suppl. 9), ix100 (2006) (Abstract 265P).
   Google Scholar
• Rose C, Vtoraya O, Pluzanska A et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur. J. Cancer39, 2318–2327 (2003).
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol.19, 3808–3816 (2001).
   PubMed Web of Science ®Google Scholar
• Cataliotti L, Buzdar AU, Noguchi S et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer106, 2095–2103 (2006).
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M, Ebbs SR et al. IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol.23, 5108–5116 (2005).
   PubMed Web of Science ®Google Scholar
• Dowsett M, A’Hern R, Smith I; on behalf of the IMPACT Trialists. Ki67 after 2 weeks’ endocrine treatment predicts relapse-free survival (RFS) in the IMPACT trial. Presented at The 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA (2005) (Abstract 45).
   Google Scholar
• Ellis MJ, Coop A, Singh B et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res.63, 6523–6531 (2003).
   PubMed Web of Science ®Google Scholar
• De Boer R Sr, Burris HA, Monnier A et al.; on behalf of the H2H trial steering committee. The head to head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. J. Clin. Oncol.24(18s), 582s (2006) (Abstract 10672).
   Google Scholar
• Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol.25(5), 486–492 (2007).
   PubMed Web of Science ®Google Scholar
• Anastrozole (Arimidex) package insert. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA (2005).
   Google Scholar
• Howell A, Cuzick J, Baum M et al. ATAC Trialists’ Group. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet365, 60–62 (2005).
   PubMed Web of Science ®Google Scholar
• Mauriac L, Keshaviah A, Debled M et al. Predictors of early recurrence in postmenopausal women with hormone receptor positive breast cancer in the BIG 1-98 trial. Ann. Oncol. (Epub ahead of print) (2007).
   PubMedGoogle Scholar
• Houghton J; on behalf of the ATAC Trialists’ Group. Initial adjuvant therapy with ANA (S) reduced rates of early breast cancer recurrent and adverse events compared with TAM (T)-data reported on behalf of the ATAC (‘Arimidex’, TAM, Alone or in Combination) Trialists’ group. Ann. Oncol.17(Suppl. 9), ix93 (2006) (Abstract 243PD).
   Google Scholar
• Viale G, Regan M, Dell’Orto P et al; The BIG 1-98 Collaborative International Breast Cancer Study Group. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Presented at The 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA (2005) (Abstract 44).
   Google Scholar
• Dowsett M, Cuzick J, Wale C et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J. Clin. Oncol.23, 7512–7517 (2005).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Allred DC; on behalf of the TransATAC Investigators. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res. Treat.100(Suppl. 1), S21 (2006) (Abstract 48).
   Google Scholar
• Mansell J, Monypenny IJ, Skene AI et al. Predictors of early recurrence in postmenopausal women with operable breast cancer. Breast Cancer Res. Treat100(Suppl. 1), S111 (2006) (Abstract 2091).
   Google Scholar
• Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J. Clin. Oncol.24, 5305–5312 (2006).
   PubMed Web of Science ®Google Scholar
• Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J. Clin. Oncol.25(7), 829–836 (2007).
   PubMed Web of Science ®Google Scholar
• Bundred N, Campbell I, Coleman R et al. Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study). Eur. J. Cancer4(Suppl.), 48 (2006)(Abstract 12).
   Google Scholar
• Garreau JR, Delamelena T, Walts D, Karamlou K, Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am. J. Surg.192, 496–498 (2006).
   PubMed Web of Science ®Google Scholar
• Presant C, Kelly C, Bosserman L et al. Aromatase inhibitor (AI)-associated arthralgia (A) and bone pain (BP): frequency and characterization in clinical practice. J. Clin. Oncol.24(18S), 334s (2006) (Abstract 6137).
   PubMedGoogle Scholar
• Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst.97, 1262–1271 (2005).
   PubMed Web of Science ®Google Scholar
• Wasan KM, Goss PE, Pritchard PH et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann. Oncol.16, 707–715 (2005).
   PubMed Web of Science ®Google Scholar
• Perez E. The balance between risks and benefits: long-term use of aromatase inhibitors. Eur. J. Cancer4(Suppl.), 16–25 (2006).
   Google Scholar
• Monnier A. Comparing AI cardiovascular safety data: trial comparators and outcomes. Ann. Oncol.17(Suppl. 9), ix100 (2006) (Abstract 266P).
   Google Scholar
• ATAC Trialists’ Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment of early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol.7, 633–643 (2006).
   PubMed Web of Science ®Google Scholar
• Coombes RC, Paridaens R, Jassem J; for the Intergroup Exemestane Study (IES). First mature analysis of the Intergroup Exemestane Study. Lancet369(9561), 559–570 (2007).
   PubMed Web of Science ®Google Scholar
• Sourander L, Rajala T, Raiha I, Makinen J, Erkkola R, Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet352, 1965–1969 (1998). Erratum in: Lancet353, 330 (1999).
   PubMed Web of Science ®Google Scholar
• Vakaet L, Buyse M. Comparative results of two adjuvant trials comparing 5 years of an aromatase inhibitor (AI) with 5 years of tamoxifen (TAM) in postmenopausal women with early breast cancer (EBC). Breast Cancer Res. Treat.100(Suppl. 1), S108–S109 (2006) (Abstract 2084).
   Google Scholar
• Moy B, Elliott CR, Chapman J-AW, Pater JL, Ding Z, Goss PE. NCIC CTG MA.27: menopausal symptoms of ethnic minority women. Breast Cancer Res. Treat.100(Suppl. 1), S144 (2006) (Abstract 3059).
   Google Scholar
• Mamounas EP, Lembersky B, Jeong JH et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin. Breast Cancer7(5), 416–421 (2006).
   PubMed Web of Science ®Google Scholar
• Jones SE. Exemestane as adjuvant treatment of early breast cancer: Intergroup Exemestane Study/Tamoxifen Exemestane Adjuvant Multicenter trials. Clin. Breast Cancer6(Suppl. 2), S41–S44 (2006).
   PubMedGoogle Scholar